Flora Growth (FLGC) Competitors

$4.28 -0.02 (-0.35%)

As of 05/22/2026

FLGC vs. QNTM, LPCN, ANEB, COCP, and NCEL

Should you buy Flora Growth stock or one of its competitors? MarketBeat compares Flora Growth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Flora Growth include Quantum Biopharma (QNTM), Lipocine (LPCN), Anebulo Pharmaceuticals (ANEB), Cocrystal Pharma (COCP), and NLS Pharmaceutics (NCEL). These companies are all part of the "pharmaceutical products" industry.

How does Flora Growth compare to Quantum Biopharma?

Quantum Biopharma (NASDAQ:QNTM) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

In the previous week, Quantum Biopharma and Quantum Biopharma both had 1 articles in the media. Flora Growth's average media sentiment score of 0.90 beat Quantum Biopharma's score of 0.15 indicating that Flora Growth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Flora Growth	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Flora Growth has higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A
Flora Growth	$57.61M	0.08	-$15.91M	-$32.49	N/A

Flora Growth has a consensus target price of $30.00, indicating a potential upside of 601.75%. Given Flora Growth's stronger consensus rating and higher possible upside, analysts clearly believe Flora Growth is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by insiders. Comparatively, 2.3% of Flora Growth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Quantum Biopharma has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-941.54%	-224.41%
Flora Growth	-32.03%	-64.02%	-34.46%

Quantum Biopharma has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market.

Summary

Flora Growth beats Quantum Biopharma on 11 of the 14 factors compared between the two stocks.

How does Flora Growth compare to Lipocine?

Lipocine (NASDAQ:LPCN) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Lipocine has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

Lipocine has higher earnings, but lower revenue than Flora Growth. Lipocine is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	9.41	-$9.63M	-$1.88	N/A
Flora Growth	$57.61M	0.08	-$15.91M	-$32.49	N/A

Flora Growth has a net margin of -32.03% compared to Lipocine's net margin of -571.18%. Flora Growth's return on equity of -64.02% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
Flora Growth	-32.03%	-64.02%	-34.46%

Lipocine presently has a consensus target price of $15.00, indicating a potential upside of 563.72%. Flora Growth has a consensus target price of $30.00, indicating a potential upside of 601.75%. Given Flora Growth's higher probable upside, analysts clearly believe Flora Growth is more favorable than Lipocine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Lipocine and Lipocine both had 1 articles in the media. Flora Growth's average media sentiment score of 0.90 beat Lipocine's score of 0.00 indicating that Flora Growth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Flora Growth	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.1% of Lipocine shares are held by institutional investors. Comparatively, 36.0% of Flora Growth shares are held by institutional investors. 6.4% of Lipocine shares are held by insiders. Comparatively, 2.3% of Flora Growth shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Flora Growth beats Lipocine on 10 of the 16 factors compared between the two stocks.

How does Flora Growth compare to Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Anebulo Pharmaceuticals has a beta of -1.93, suggesting that its share price is 293% less volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Comparatively, 2.3% of Flora Growth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Anebulo Pharmaceuticals and Anebulo Pharmaceuticals both had 1 articles in the media. Flora Growth's average media sentiment score of 0.90 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Flora Growth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anebulo Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Flora Growth	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Flora Growth has a consensus target price of $30.00, indicating a potential upside of 601.75%. Given Flora Growth's stronger consensus rating and higher probable upside, analysts clearly believe Flora Growth is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Anebulo Pharmaceuticals has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Flora Growth	-32.03%	-64.02%	-34.46%

Anebulo Pharmaceuticals has higher earnings, but lower revenue than Flora Growth. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
Flora Growth	$57.61M	0.08	-$15.91M	-$32.49	N/A

Summary

Flora Growth beats Anebulo Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Flora Growth compare to Cocrystal Pharma?

Flora Growth (NASDAQ:FLGC) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Flora Growth has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

In the previous week, Flora Growth had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 1 mentions for Flora Growth and 0 mentions for Cocrystal Pharma. Flora Growth's average media sentiment score of 0.90 beat Cocrystal Pharma's score of 0.00 indicating that Flora Growth is being referred to more favorably in the media.

Company	Overall Sentiment
Flora Growth	Positive
Cocrystal Pharma	Neutral

36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 2.3% of Flora Growth shares are owned by company insiders. Comparatively, 28.1% of Cocrystal Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cocrystal Pharma has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flora Growth	-32.03%	-64.02%	-34.46%
Cocrystal Pharma	N/A	-150.61%	-97.86%

Cocrystal Pharma has lower revenue, but higher earnings than Flora Growth. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flora Growth	$57.61M	0.08	-$15.91M	-$32.49	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A

Flora Growth presently has a consensus price target of $30.00, indicating a potential upside of 601.75%. Cocrystal Pharma has a consensus price target of $6.00, indicating a potential upside of 421.74%. Given Flora Growth's higher probable upside, analysts clearly believe Flora Growth is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Flora Growth beats Cocrystal Pharma on 9 of the 13 factors compared between the two stocks.

How does Flora Growth compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

In the previous week, Flora Growth had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 1 mentions for Flora Growth and 0 mentions for NLS Pharmaceutics. Flora Growth's average media sentiment score of 0.90 beat NLS Pharmaceutics' score of 0.00 indicating that Flora Growth is being referred to more favorably in the news media.

Company	Overall Sentiment
NLS Pharmaceutics	Neutral
Flora Growth	Positive

36.0% of Flora Growth shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by insiders. Comparatively, 2.3% of Flora Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

NLS Pharmaceutics has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. NLS Pharmaceutics' return on equity of 0.00% beat Flora Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Flora Growth	-32.03%	-64.02%	-34.46%

NLS Pharmaceutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market.

Flora Growth has a consensus target price of $30.00, indicating a potential upside of 601.75%. Given Flora Growth's stronger consensus rating and higher possible upside, analysts plainly believe Flora Growth is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

NLS Pharmaceutics has higher earnings, but lower revenue than Flora Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Flora Growth	$57.61M	0.08	-$15.91M	-$32.49	N/A

Summary

Flora Growth beats NLS Pharmaceutics on 8 of the 13 factors compared between the two stocks.

Get Flora Growth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLGC vs. The Competition

Export

Metric	Flora Growth	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.47M	$8.52B	$6.46B	$12.34B
Dividend Yield	N/A	2.50%	2.76%	5.28%
P/E Ratio	-0.13	16.24	21.00	25.66
Price / Sales	0.08	8.28	558.19	86.31
Price / Cash	N/A	17.11	43.49	56.67
Price / Book	0.35	4.06	10.40	7.14
Net Income	-$15.91M	$224.05M	$3.57B	$335.98M
7 Day Performance	5.56%	5.34%	6.40%	4.11%
1 Month Performance	-36.00%	-0.08%	3.55%	2.52%
1 Year Performance	-84.39%	0.98%	34.13%	35.04%

Flora Growth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLGC Flora Growth	2.282 of 5 stars	$4.28 -0.3%	$30.00 +601.8%	-84.4%	$4.47M	$57.61M	N/A	280	Gap Up
QNTM Quantum Biopharma	0.3048 of 5 stars	$5.20 +2.8%	N/A	-20.0%	$19.31M	N/A	N/A	N/A	Gap Down
LPCN Lipocine	2.9104 of 5 stars	$2.33 +0.4%	$15.00 +543.8%	-36.9%	$19.13M	$1.98M	N/A	10
ANEB Anebulo Pharmaceuticals	0.0325 of 5 stars	$0.52 +13.0%	$3.00 +476.9%	-58.9%	$18.76M	N/A	N/A	4	Gap Up
COCP Cocrystal Pharma	1.9885 of 5 stars	$1.31 +0.8%	$6.00 +358.0%	-21.2%	$17.92M	N/A	N/A	10	Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLGC) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Flora Growth (FLGC) Competitors

FLGC vs. QNTM, LPCN, ANEB, COCP, and NCEL

How does Flora Growth compare to Quantum Biopharma?

Summary

How does Flora Growth compare to Lipocine?

Summary

How does Flora Growth compare to Anebulo Pharmaceuticals?

Summary

How does Flora Growth compare to Cocrystal Pharma?

Summary

How does Flora Growth compare to NLS Pharmaceutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGC vs. The Competition

Flora Growth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Flora Growth (FLGC) Competitors

FLGC vs. QNTM, LPCN, ANEB, COCP, and NCEL

How does Flora Growth compare to Quantum Biopharma?

Does the media prefer QNTM or FLGC?

Which has better earnings & valuation, QNTM or FLGC?

Do analysts rate QNTM or FLGC?

Do insiders and institutionals believe in QNTM or FLGC?

Is QNTM or FLGC more profitable?

Which has more risk & volatility, QNTM or FLGC?

Summary

How does Flora Growth compare to Lipocine?

Which has more risk & volatility, LPCN or FLGC?

Which has better earnings and valuation, LPCN or FLGC?

Is LPCN or FLGC more profitable?

Do analysts prefer LPCN or FLGC?

Does the media prefer LPCN or FLGC?

Do institutionals and insiders believe in LPCN or FLGC?

Summary

How does Flora Growth compare to Anebulo Pharmaceuticals?

Which has more risk and volatility, ANEB or FLGC?

Do institutionals & insiders believe in ANEB or FLGC?

Does the media refer more to ANEB or FLGC?

Do analysts rate ANEB or FLGC?

Is ANEB or FLGC more profitable?

Which has higher earnings & valuation, ANEB or FLGC?

Summary

How does Flora Growth compare to Cocrystal Pharma?

Which has more volatility and risk, FLGC or COCP?

Does the media favor FLGC or COCP?

Do institutionals and insiders have more ownership in FLGC or COCP?

Is FLGC or COCP more profitable?

Which has stronger earnings and valuation, FLGC or COCP?

Do analysts rate FLGC or COCP?

Summary

How does Flora Growth compare to NLS Pharmaceutics?

Does the media refer more to NCEL or FLGC?

Do insiders and institutionals hold more shares of NCEL or FLGC?

Is NCEL or FLGC more profitable?

Which has more risk and volatility, NCEL or FLGC?

Do analysts prefer NCEL or FLGC?

Which has higher valuation & earnings, NCEL or FLGC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGC vs. The Competition

Flora Growth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools